Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BZL 101

Drug Profile

BZL 101

Alternative Names: Bezielle; BZL-101

Latest Information Update: 20 Jan 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bionovo
  • Class Antineoplastics; Phytotherapies
  • Mechanism of Action Apoptosis stimulants; Glycolysis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Pancreatic cancer

Most Recent Events

  • 12 Mar 2012 No development reported - Preclinical for Pancreatic cancer in USA (PO)
  • 06 Feb 2012 Bionovo plans a phase II trial for Breast cancer in USA (NCT00907959)
  • 02 Nov 2010 Bionovo receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA) for controlled-release BZL 101 development in Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top